Glioblastoma as an age-related neurological disorder in adults.



Advanced age is a major risk factor for the development of many diseases including those affecting the central nervous system. Wild-type isocitrate dehydrogenase glioblastoma (IDHwt GBM) is the most common primary malignant brain cancer and accounts for ≥90% of all adult GBM diagnoses. Patients with IDHwt GBM have a median age of diagnosis at 68-70 years of age, and increasing age is associated with an increasingly worse prognosis for patients with this type of GBM.


The Surveillance, Epidemiology, and End Results, The Cancer Genome Atlas, and the Chinese Glioma Genome Atlas databases were analyzed for mortality indices. Meta-analysis of 80 clinical trials was evaluated for log hazard ratio for aging to tumor survivorship.


Despite significant advances in the understanding of intratumoral genetic alterations, molecular characteristics of tumor microenvironments, and relationships between tumor molecular characteristics and the use of targeted therapeutics, life expectancy for older adults with GBM has yet to improve.


Based upon the results of our analysis, we propose that age-dependent factors that are yet to be fully elucidated, contribute to IDHwt GBM patient outcomes.





Published Version (Please cite this version)


Publication Info

Kim, Miri, Erik Ladomersky, Andreas Mozny, Masha Kocherginsky, Kaitlyn O'Shea, Zachary Z Reinstein, Lijie Zhai, April Bell, et al. (2021). Glioblastoma as an age-related neurological disorder in adults. Neuro-oncology advances, 3(1). p. vdab125. 10.1093/noajnl/vdab125 Retrieved from

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.



Quinn Ostrom

Assistant Professor in Neurosurgery

I am a cancer epidemiologist with specialized training in genetic epidemiology. The overall goal of my research program is to identify genetic factors that increase the risk of developing a brain tumor as well as those that affect prognosis after diagnosis. My research focuses on: 1) using population-level cancer registry data for surveillance and risk factor discovery; 2) discovering sources of germline genetic risk for brain tumors and 3) understanding the relationship between immune traits and brain tumor risk and survival. I approach these questions through a research program of interrelated projects and application of novel analytic techniques.


Margaret Johnson

Assistant Professor of Neurosurgery

I am a neuro-oncologist, neurologist, and palliative care physician at the Preston Robert Tisch Brain Tumor Center. I also provide neuro-oncology expertise for the National Tele-Oncology Program and National Precision Oncology Program at the Veteran's Health Administration. My clinical and research interests encompass supportive care and palliative care with a special interest in older adults with brain tumors. The incidence of malignant brain tumors like glioblastoma and non-malignant tumors like meningioma affect aging populations and it is crucial to be able to provide better care for these patients. 

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.